课题基金 / 基金详情

Development of Aersolized Vaccines

Development of Aersolized Vaccines
雾化疫苗的开发
批准号:
7592437
负责人:
Mario Roederer
金额:
$45.97万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

Mario Roederer的其他基金

相似基金

相关文献

中文摘要
翻译
我们已经证明,当将重组腺病毒雾化到恒河猴的肺部时,具有高度的免疫原性。具体来说,这种免疫在肺部产生非常高水平的持续性CD4和CD8 T细胞反应,尽管在身体其他部位的水平非常低。有趣的是,我们还发现在全身和不同的粘膜部位都能产生很好的抗体反应。因此,这一途径可能对产生黏膜免疫反应非常重要,而黏膜免疫反应是抵御HIV等挑战所必需的。但可以肯定的是,高水平的肺细胞反应对于预防肺结核或流感是理想的;我们正在用病媒对这些病原体进行免疫,并测试是否能看到保护作用。
英文摘要
We have demonstrated that aerosolized recombinant adenovirus is highly immunogenic when delivered to the lung of rhesus macaques. Specifically, this immunization generates very high levels of persistent CD4 and CD8 T cell responses in the lung, although very low levels throughout the rest of the body. Interestingly, we also find very good generation of antibody responses, both throughout the body and at various mucosal sites. Thus, this route may be very important for the generation of mucosal immune responses needed to protect against challenges such as HIV. But certainly, the high lung cellular responses are ideal for the possible protection against tuberculosis or influenza; we are in the process of immunizing with vectors against these pathogens and testing whether or not protection is seen.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Develop Of Flow Cytometric Technologies For Immune Assay
Identification of HIV-specific B cells in blood
Development Of Flow Cytometric Technologies For Immune Assays
Non-Human Primate Core
海外基金